| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/07/2013 | CA2746516C Non-polar photosensitizer formulations for photodynamic therapy |
| 05/07/2013 | CA2744932C Nalmefene hydrochloride dihydrate |
| 05/07/2013 | CA2735267C Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 05/07/2013 | CA2715662C Phenylpropanoid diglycerides for the treatment of cancer |
| 05/07/2013 | CA2702710C Trans-clomiphene for metabolic syndrome |
| 05/07/2013 | CA2694911C Substituted piperazinyl pyrazines and pyridines as 5-ht7 receptor antagonists |
| 05/07/2013 | CA2681712C Tamibarotene capsule preparation |
| 05/07/2013 | CA2621015C New use for a composition comprising chloroprocaine hcl, a new composition comprising chloroprocaine hcl and a method for its manufacture |
| 05/07/2013 | CA2620553C Therapeutic agent for hypertension |
| 05/07/2013 | CA2615121C Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion |
| 05/07/2013 | CA2607299C Compounds and compositions as protein kinase inhibitors |
| 05/07/2013 | CA2598460C Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| 05/07/2013 | CA2596618C Isolation of n-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of n-butylbenzenesulfonamide and benzenesulfonamide derivatives for treating benign prostatic hyperplasia and/or prostate carcinoma |
| 05/07/2013 | CA2590349C Potentiators of glutamate receptors |
| 05/07/2013 | CA2584448C Hydroxybenzoate salts of metanicotine compounds |
| 05/07/2013 | CA2581379C Calcium trifluoroacetate for the treatment of plasma cell neoplasias |
| 05/07/2013 | CA2575081C Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
| 05/07/2013 | CA2574827C 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 05/07/2013 | CA2568752C Novel unsaturated tetracyclic tetrahydrofuran derivatives |
| 05/07/2013 | CA2558029C Ion binding polymers and uses thereof |
| 05/07/2013 | CA2557479C Biphenyl compounds useful as muscarinic receptor antagonists |
| 05/07/2013 | CA2557354C Alkaloid formulations |
| 05/07/2013 | CA2554071C A-type procyanidins useful in the treatment of nitric oxide mediated disorders |
| 05/07/2013 | CA2551956C Selective estrogen receptor modulators for the treatment of vasomotor symptoms |
| 05/07/2013 | CA2538864C Thalidomide analogs as tnf-alpha modulators |
| 05/07/2013 | CA2534645C Composition and method for promoting hair growth |
| 05/07/2013 | CA2531566C Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| 05/07/2013 | CA2516651C Methods of screening for trpm5 modulators |
| 05/07/2013 | CA2514100C Carboxamide derivatives and the use thereof as factor xa inhibitors |
| 05/07/2013 | CA2507334C Pyrimidine-sulfamides and their use as endothelian receptor antagonist |
| 05/07/2013 | CA2496376C Methods of drug delivery using sulphated chitinous polymers |
| 05/07/2013 | CA2491131C Novel compounds as histone deacetylase inhibitors |
| 05/07/2013 | CA2486714C Compositions for penis enlargement |
| 05/07/2013 | CA2475073C Hypoallergenic polypeptides based on fish parvalbumin |
| 05/07/2013 | CA2467053C Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 05/07/2013 | CA2459562C Synthetic heparin pentasaccharides |
| 05/07/2013 | CA2456184C Expression profile of prostate cancer |
| 05/07/2013 | CA2438032C Benzothiazole derivative compounds, compositions and uses |
| 05/07/2013 | CA2360347C Improved expression of hiv polypeptides and production of virus-like particles |
| 05/02/2013 | WO2013063585A1 Aqueous compositions for bone hemostasis, and methods for their use and manufacture |
| 05/02/2013 | WO2013063580A1 Nonaqueous compositions for bone hemostasis, and methods for their use and manufacture |
| 05/02/2013 | WO2013063560A2 INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION |
| 05/02/2013 | WO2013063549A1 Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| 05/02/2013 | WO2013063536A1 Actriib binding agents and uses thereof |
| 05/02/2013 | WO2013063526A1 Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| 05/02/2013 | WO2013063512A1 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| 05/02/2013 | WO2013063504A1 Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells |
| 05/02/2013 | WO2013063496A1 Biomarkers of response to nae inhibitors |
| 05/02/2013 | WO2013063492A1 Novel compositions and methods for treating cancer |
| 05/02/2013 | WO2013063462A2 Method of treating hcv infection with a small molecule chk2 inhibitor |
| 05/02/2013 | WO2013063459A1 Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
| 05/02/2013 | WO2013063458A2 Inhibiting g protein coupled receptor 6 kinase polypeptides |
| 05/02/2013 | WO2013063417A1 Methyltransferase inhibitors for treating cancer |
| 05/02/2013 | WO2013063413A1 Treatment of rhinitis |
| 05/02/2013 | WO2013063385A1 Compounds for inflammation and immune-related uses |
| 05/02/2013 | WO2013063331A1 Agents, methods, and devices for affecting nerve function |
| 05/02/2013 | WO2013063321A1 Wnt/b-catenin inhibitors and methods of use |
| 05/02/2013 | WO2013063271A1 Artemisinin and berberine compositions and methods of making |
| 05/02/2013 | WO2013063269A2 Compounds and methods of treating ocular disorders |
| 05/02/2013 | WO2013063263A1 Pharmaceutical compositions for treating pain |
| 05/02/2013 | WO2013063243A1 Small molecule malarial aldolase-trap enhancers and glideosome inhibitors |
| 05/02/2013 | WO2013063221A1 Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
| 05/02/2013 | WO2013063217A1 Fused bicyclic oxazolidinone cetp inhibitor |
| 05/02/2013 | WO2013063216A1 5-nonyloxytrptamine and related intracellular ph acidifiers for the treatment and prevention of cancer |
| 05/02/2013 | WO2013063204A1 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof |
| 05/02/2013 | WO2013063149A1 Sialic acid analogs |
| 05/02/2013 | WO2013063127A1 Cyclohexylamines |
| 05/02/2013 | WO2013063100A1 Allosteric modulators of metabotropic glutamate receptors |
| 05/02/2013 | WO2013063082A1 Implantable rasagiline compositions and methods of treatment thereof |
| 05/02/2013 | WO2013063079A1 Implantable tizanidine compositions and methods of treatment thereof |
| 05/02/2013 | WO2013063072A1 Method for the formulation of hand sanitizer |
| 05/02/2013 | WO2013063068A1 Factor ixa inhibitors |
| 05/02/2013 | WO2013063049A1 Orally-administered plastid expressed cholera toxin b subunit-exendin 4 as treatment for type 2 diabetes |
| 05/02/2013 | WO2013063017A1 Diagnosis and treatment of mesothelioma |
| 05/02/2013 | WO2013063012A1 Myxovirus therapeutics, compounds, and uses related thereto |
| 05/02/2013 | WO2013063003A1 Method of treating gastrointestinal stromal tumors |
| 05/02/2013 | WO2013063000A1 Method of treating gastrointestinal stromal tumors |
| 05/02/2013 | WO2013062984A1 Method for treatment of mesothelioma |
| 05/02/2013 | WO2013062947A1 Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators |
| 05/02/2013 | WO2013062945A1 Chemical compounds |
| 05/02/2013 | WO2013062943A1 New compounds |
| 05/02/2013 | WO2013062923A1 MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| 05/02/2013 | WO2013062900A1 Inhibitors of the renal outer medullary potassium channel |
| 05/02/2013 | WO2013062892A1 Inhibitors of the renal outer medullary potassium channel |
| 05/02/2013 | WO2013062887A1 Substituted pyridine derivatives useful as gpr131 agonists |
| 05/02/2013 | WO2013062882A1 Scd inhibitors for the treatment of hcv |
| 05/02/2013 | WO2013062881A1 Process for making beta 3 agonists and intermediates |
| 05/02/2013 | WO2013062878A1 Process for making beta 3 angonists and intermediates |
| 05/02/2013 | WO2013062857A1 Piperidinyl alkyne orexin receptor antagonists |
| 05/02/2013 | WO2013062843A1 Pyridine- sulfoximines as tyrosine kinase inhibitors |
| 05/02/2013 | WO2013062838A1 Substituted piperidinyl compounds useful as gpr119 agonists |
| 05/02/2013 | WO2013062837A1 Piperidine derivatives useful as gpr119 agonists |
| 05/02/2013 | WO2013062835A1 Substituted piperidinyl compounds useful as gpr119 agonists |
| 05/02/2013 | WO2013062762A1 Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies |
| 05/02/2013 | WO2013062680A1 Novel compounds and compositions thereof for treating nervous system disorders |
| 05/02/2013 | WO2013062544A1 Cysteamine in the treatment of fibrotic disease |
| 05/02/2013 | WO2013062498A1 Solid oral formulations comprising ebastine |
| 05/02/2013 | WO2013062497A1 Liquid pharmaceutical formulations |
| 05/02/2013 | WO2013062445A1 Pharmaceutical composition and kit for treating bacterial infections |
| 05/02/2013 | WO2013062441A1 Pharmaceutical combination of atorvastatin and nicergoline for the prophylaxis or treatment of disorders of the cerebral circulation |